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Successful MDR-TB treatment regimens including
Amikacin are associated with high rates of hearing
loss
Chawangwa Modongo1,2,3, Rafal S Sobota4, Boikobo Kesenogile3,5, Ronald Ncube6, Giorgio Sirugo7,
Scott M Williams4 and Nicola M Zetola1,2,3*
Abstract
Background: Aminoglycosides are a critical component of multidrug-resistant tuberculosis (MDR-TB) treatment but
data on their efficacy and adverse effects in Botswana is scarce. We determined the effect of amikacin on treatment
outcomes and development of hearing loss in MDR-TB patients.
Methods: Patients started on MDR-TB treatment between 2006 and 2012 were included. Multivariate analysis was
used to determine the effect of amikacin on treatment outcomes and development of hearing loss.
Results: 437 MDR-TB patients were included, 288 (66%) of whom were HIV co-infected. 270 (62%) developed
hearing loss, of whom 147 (54%) had audiometry. Of the 313 (72%) patients who completed treatment, 228
(73%) had a good outcome (cure or treatment completion). Good outcome was associated with longer amikacin
treatment (adjusted OR [aOR] 1.13, 95% CI 1.06 - 1.21) and higher dosage (aOR 1.90, 95% CI 1.12 – 2.99). Longer
amikacin duration (aOR 1.98, 95% CI 1.86 – 2.12) and higher dosage per weight per month (aOR 1.15, 95%
CI 1.04 – 1.28) were associated with development of hearing loss. Amikacin treatment duration modified the
effect of the dosage on the risk of hearing loss, increasing this risk as the duration increased.
Conclusions: Amikacin was effective for MDR-TB treatment, but was associated with a high incidence of hearing loss
especially in our study population. Total treatment duration and average monthly amikacin dose were associated with
improved outcomes; however these were also associated with development of hearing loss.
Keywords: Hearing loss, Aminoglycosides, Amikacin, Multi-drug resistant tuberculosis, HIV
Background
Multidrug-resistant tuberculosis (MDR-TB) is caused by a
Mycobacterium tuberculosis isolate that does not respond
to isoniazid and rifampicin, the two most effective first-
line antituberculous treatment (ATT) drugs. MDR-TB
usually fails to respond to the conventional first-line ATT
but is curable with second-line drugs. However, those
drugs are limited in number and less effective. Fluoro-
quinolones and aminoglycosides (AGs) constitute the core
of all currently recommended MDR-TB regimens [1-4].
Aminoglycosides are the cheapest and most accessible
injectable antituberculous drugs. Therefore AGs are the
injectable drugs of choice in most resource limited settings
and also the ones recommended by the World Health
Organization (WHO) guidelines [4,5]. Similar to many
other developing countries, Botswana has adopted a
standardized MDR-TB regimen that included amikacin
as the injectable drug of choice [5].
Aminoglycosides are potent antibacterials but also have
substantial toxicity, potentially causing irreversible hearing
loss. AG-induced hearing loss can occur sporadically, in a
dose-dependent manner or based on genetic predispos-
ition [6-9]. In resource-rich countries, the use of most
AGs has been restricted to the treatment of gram-negative
organisms. With this shift in the primary use of AGs,
there was also a shift in the study of their toxicity. Over
the last few decades, AG-related studies have focused on
* Correspondence: nzetola@gmail.com
1Division of Infectious Diseases, University of Pennsylvania, Philadelphia,
Pennsylvania, USA
2Botswana-University of Pennsylvania Partnership, 214 Independence
Avenue, Gaborone, Botswana
Full list of author information is available at the end of the article
© 2014 Modongo et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Modongo et al. BMC Infectious Diseases 2014, 14:542
http://www.biomedcentral.com/1471-2334/14/542
shorter treatment courses in hospitalized patients with
gram-negative bacterial infections or on their use as syner-
gistic agents [10-12]. In addition, most of those studies
were performed in the pre-HIV era [13-17]. Thus, al-
though many studies have described the toxic effects of
AGs, the overall incidence of long term AG-associated
hearing loss and risk factors predisposing patients to hear-
ing loss remain disputed [18-20].
Given the lack of data, AGs dosages and treatment
duration have been extrapolated from the experience in
resource-rich settings to treatment of drug-susceptible
TB. Specific data on AG-based regimens for the treat-
ment of MDR-TB are limited and are particularly scarce
in patients co-infected with MDR-TB and HIV [21,22].
We analyzed the effects of amikacin-based regimens on
the treatment outcomes of MDR-TB patients and the






All MDR-TB patients 15 years of age and above who
were started on MDR-TB treatment between January 01,
2006 and June 30, 2012 were eligible for the study
[23-25]. We included all patients who had at least one
baseline serum creatinine measurement (defined as cre-
atinine measurement within 1 month prior to or one
month after the start of amikacin) and one follow-up
creatinine measurement (within the last 6 months prior
to censoring). Patients who were deaf before initiation of
MDR-TB treatment (defined by audiogram as an inabil-
ity to detect sound at amplitude of 20 dB in a frequency
range from 800 to 1,800 vibrations per second or by
functionality as the absence of usable hearing) were ex-
cluded from the analysis.
Setting and procedures
This study was conducted in Botswana, a sub-Saharan
African country with HIV prevalence of 18% and a TB
rate of 503/100,000 population [26,27]. As per the na-
tional guidelines, all MDR-TB patients are referred to
one of 5 specialized government TB clinics located
around the country. These clinics served as the study
sites. MDR-TB patients were placed on a standardized
MDR-TB regimen whilst waiting for the second-line
drug susceptibility test (DST) results [5]. The standard-
ized MDR-TB regimen was composed of amikacin, levo-
floxacin, ethionamide, cycloserine, and pyrazinamide.
Individualized regimens were provided after the second-
line DST results were available [5]. The MDR-TB treat-
ment was administered daily at the observation clinic.
Amikacin dosage was calculated according to the WHO
recommendations and adjusted for renal function [2].
Dosages raging between 15 and 25 milligram (mg) per
kilogram (kg) intramuscularly (with a maximum dosage
of 1000 mg per day) were administered. Amikacin was
administered once daily, seven days per week, and chan-
ged to three times per week after culture conversion on
patients who had hearing loss. The injection was then
discontinued 4 months after culture conversion. At the
time of analysis, audiometry (using GSI 61 audiometer)
was not routine care for MDR-TB patients. High fre-
quency audiometry was performed on some patients
who reported hearing loss; follow-up on those with
audiometry was performed every three months until
3 months after stopping amikacin.
Patients were treated for a minimum of 18 months
after culture conversion. Clinical assessment and mea-
surements, including weight, serum creatinine, sputum
microscopy, cultures and DSTs were performed monthly
[28-30]. An HIV test was performed on all patients with
no documentation of infection [31].
Data collection
Data was extracted from medical records and electronic da-
tabases at the TB clinics, Botswana National Tuberculosis
Program, and Botswana National Tuberculosis Reference
Laboratory. Data collected included patient demographics,
semi-quantitative bacillary load by microscopy at the time
of diagnosis (acid fast bacilli, [AFB]), extrapulmonary in-
volvement, HIV status, and CD4+ cell count, along with
the use of antiretroviral therapy (ART) in HIV-positive
cases. All study participants (including those with evidence
of concomitant extrapulmonary disease) had microbio-
logical proof of pulmonary TB (PTB). TB was classified as
unilateral or bilateral and cavitary or non-cavitary based on
radiologic findings on chest X-rays. TB patients were also
classified as having TB alone or PTB plus extrapulmonary
involvement. Each month, mycobacterial culture results,
DST results, number of antituberculosis drugs active at
baseline, and average dose per kilogram of the injectable
drug were collected.
Outcome variables
We used two primary outcomes for our analyses:
a) Hearing loss. We used two different definitions for
hearing loss. Hearing loss confirmed by audiometry
(our main outcome) was defined as an increase of
15 dB in pure tone threshold at two or more
frequencies or an increase of more than 20 dB at
one frequency. Among patients who did not
undergo audiometry, clinical deafness was diagnosed
by the treating physician functionally as absence of
usable hearing acquired during or soon after (within
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6 months after) amikacin treatment. In addition, we
also used a composite outcome which combined all
patients with audiometry-defined or clinically-defined
hearing loss.
b) Treatment outcome. We used the updated WHO
definitions for treatment outcomes [32]. “Cure” was
defined as MDR-TB patients who have completed
treatment according to programme protocol without
evidence of failure and had three or more consecutive
negative cultures taken at least 30 days apart after the
intensive phase. “Treatment completion” was MDR-TB
patients who had completed treatment according to
programme protocol without evidence of failure but
with no record that three or more consecutive negative
cultures were taken at least 30 days apart after the
intensive phase. “Death” was defined as MDR-TB
patients who die for any reason during the course of
treatment. “Treatment failure” was defined as treatment
terminated or need for permanent regimen change of
at least two anti-TB drugs because of; lack of culture
conversion (defined as two negative consecutive
cultures taken at least 30 days apart; specimen collec-
tion date of the first negative culture was used as date
of conversion) by the end of intensive phase, or
bacteriological reversion (defined as two consecutive
cultures taken at least 30 days apart, were found to be
positive after initial conversion). Reversion was consid-
ered only when it occurred in the continuation phase
after conversion to negative or if there was evidence of
additional acquired resistance to fluoroquinolones or
second-line injectable drugs. “Lost to follow-up” was
used to describe MDR-TB patients whose treatment
was interrupted for two or more consecutive months
for any reason without medical approval [32]. For our
main analyses, clinical outcome was defined as good
(i.e., cure or completion of treatment) or poor
(i.e., treatment failure, lost to follow-up or death).
Statistical analysis
Categorical variables were summarized using frequencies
and proportions, and continuous variables were summa-
rized using mean values and medians. Differences in
baseline characteristics of exposed and unexposed pa-
tients were assessed using chi-squared and t-tests or
Wilcoxon rank-sum tests, as appropriate.
Our main exposures of interest were amikacin treat-
ment duration (in months) and mean monthly amikacin
dosage (per kg, per month). We performed two different
analyses, for which we used different primary outcomes.
The first analysis aimed at identifying factors associ-
ated with the development of hearing loss. We per-
formed three independent analyses using the above
mentioned definitions of hearing loss (audiometry, clin-
ical and audiometry plus clinical hearing loss). We used
Pearson’s correlation coefficient to quantify the correl-
ation between audiometry-defined and clinically-defined
hearing loss. Patients who were still on treatment at the
time of analysis (and did not have treatment outcomes)
were excluded from these analyses.
Our data were not independent because of repeated
measures on the same individuals over time. Thus, multi-
level mixed-effect logistic regression models were used to
calculate crude and adjusted odds ratios (aORs) and corre-
sponding 95% confidence intervals (CIs) and to assess
confounding. Mixed-effect logistic regression models en-
abled the correlations between repeated measures to be
taken into account. We built these models to accommo-
date the correlation inherent in our data and account for
clustering. A post estimation test, “Wald test” for simple
and composite linear hypotheses about the parameters of
a fitted model were computed to compare levels of multi-
level variables. Pearson’s correlation test was also con-
ducted to determine the correlation between cluster-level
independent variables included in the models. Variance
components were estimated using the restricted max-
imum likelihood method. We tested for presence of a stat-
istical interaction between mean monthly amikacin dose
per kilogram (Kg) and duration of amikacin treatment
(in months) using a heterogeneity test.
Potential confounders included age, sex, prior TB history,
baseline weight, and HIV. For analyses restricted to those
with HIV, we also evaluated the CD4+ T cell count and use
of anti-retroviral therapy (ART) at baseline as potential
confounders. Potential confounders were considered actual
confounders if their inclusion in the multivariable model
changed the unadjusted ORs by 10% or more. We also de-
termined if severity of TB disease was worse among those
patients who developed hearing loss. However, adjusting
for severity of disease could adjust for factors on the causal
pathway between exposure (amikacin dose and time) and
treatment outcome if the exposure affects risk of poor out-
comes via worsening the severity of TB disease (e.g. higher
dose of amikacin given to sicker patients, leading to renal
failure). Factors indicating severity of disease included
semi-quantitative bacillary load (by AFB microscopy:
scanty, 1+, 2+ and 3+). Once our final model was se-
lected, we assessed its reliability using a split-sample
analysis. To develop the covariance model, we started
with an unstructured covariance structure and then
compared the fits of several other covariance struc-
tures using comparisons of likelihoods and information
criteria. Finally, an unstructured covariance structure was
selected because of substantial reduction in the likelihood
when compared with other covariance structures.
The variables included in the “maximum model” were
baseline weight, TB history, prior exposure to ATT, ex-
tent of radiological infiltrates (unilateral vs. bilateral),
presence of cavitary lesions on the chest X-ray, and
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semi-quantitative bacillary load determined by micros-
copy. To account for potential differences in treatment
that may affect outcomes, we adjusted for indicators of
the appropriateness of treatment, including treatment
duration with an injectable drug, the number of effective
drugs used during the initial empirical therapy and the indi-
vidualized therapy following the availability of second-line
DST results. HIV infection, concomitant administration of
ART and baseline CD4+ T cell count were also accounted
for, where appropriate. Time-dependent variables included
culture and DST results, monthly average number of TB
drugs active against the MDR-TB isolate as indicated by
prior culture, and monthly amikacin injectable dosage. Cre-
atinine clearance was calculated using Cockcroft-Gault for-
mula using monthly serum creatinine collected [33-36].
The second analysis aimed to determine the effect of
amikacin over treatment outcomes. Treatment outcomes
were first based on the WHO definitions [32] and then
dichotomized as “poor” or “good”. Poor treatment out-
come was defined as treatment failure, lost to follow-up,
or death. Good treatment outcome was defined as bac-
teriological cure or completion of treatment. For this
analysis, individuals were followed from MDR-TB treat-
ment initiation date until they experienced a poor treat-
ment outcome or were censored, which occurred if they
remained on ATT at the end of observation or were
lost to follow-up (>2 months since last visit) or at the
end of observation (June 30, 2012), whichever came
first. Collinearity was assessed by measuring variance
inflation factors. Highly collinear variables were taken
out from the model or, if they were considered import-
ant for the theoretical model, they were included one
at a time.
Ethics
This study was approved by the Human Research Develop-
ment Committee at the Ministry of Health, Botswana, and
the University of Pennsylvania Institutional Review Board.
Results
Cohort and study population
Of the 437 MDR-TB patients who met the inclusion cri-
teria, 240 (55%) were male and 197 (45%) females. The
median age was 38 years (interquartile range [IQR], 31-49).
A total of 256 (59%) patients had previous streptomycin
use, and 12 (3%) had previous amikacin use. The HIV sta-
tus was available for all patients, and 288 (66%) were HIV-
positive (Table 1). For those with no documented hearing
loss, treatment was successful in 60 (36%) patients while
29 (17.4%) died during follow-up.
Factors associated with amikacin-related hearing loss
Overall, hearing loss was diagnosed in 270 (62%) pa-
tients. Of them, 147 (54%) had audiogram confirmation.
There was a perfect correlation between our definition
of clinical deafness and severe hearing loss by audiom-
etry (Pearson coefficient = 1.0) and no clustering was
found. The diagnosis of hearing loss occurred at a me-
dian time of 170 days (IQR, 104-212 days) in those con-
firmed by audiogram and 167 days (IQR, 108-214 days)
those without audiogram after amikacin initiation. Most
patients (329, 75.5%) received the WHO recommended
dosage range for their weight and renal function during
the entire duration of treatment. Fifteen (3%) patients
halted amikacin due to adverse effects other than hearing
loss, and 316 (72%) completed the course. Eight (2%)
patients died whilst on amikacin (Table 2).
Our multivariate analyses showed that none of the
demographic variables were associated with develop-
ment of hearing loss. Similarly, HIV infection was not
associated with increased risk of hearing loss. The most
important risk factors for hearing loss were amikacin
treatment duration (aOR 1.98; 95% CI 1.86-2.12, Table 3)
and amikacin dosage (aOR 1.15; 95% CI 1.04-1.28,
Table 3). The independent effect of a higher amikacin
dosage on the risk of hearing loss was present even
when dosages were within the recommended range for
patients’ weight and renal function during the entire
duration of treatment (data not shown). There was a
strong positive interaction between amikacin treatment
duration and dosage administered (Table 3).
Factors associated with good clinical outcomes
Our final multivariate model accounted for prior history
of TB, prior TB treatment (for drug susceptible and
MDR-TB), renal failure and HIV status. Demographic
variables included in our models did not contribute to
goodness of fit (Table 4). MDR-TB treatment and devel-
opment of renal failure at any point during treatment
were risk factors for poor treatment outcome. Longer
duration (aOR 1.14, 95% CI 1.06 - 1.21) and a higher
dosage of amikacin treatment (aOR 1.90, 95% CI 1.79 -
3.00) were associated with good outcome. Development of
hearing loss during the treatment course was strongly asso-
ciated with good outcome (aOR 3.29, 95% CI 1.77 – 6.10).
Discussion
Our MDR-TB program achieved high rates of treatment
success and our results support the inclusion of amika-
cin in the MDR-TB regimen. However, we also found
that prolonged amikacin therapy and higher dosages per
kg were associated with high incidence of hearing loss.
Further, we found an interaction between dose and time
of amikacin treatment. These data suggest that both
good treatment outcomes and hearing loss are associ-
ated with higher amikacin dosages and longer adminis-
tration durations highlighting one of the major issues
that policy makers and clinicians face with regard to use
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of amikacin in MDR-TB patients: how can one balance
the efficacy of treatment and the risk of deafness.
The bactericidal effect of AGs is concentration-dependent,
meaning that increasing AG concentration kills an increas-
ing proportion of mycobacteria at a higher rate. This prop-
erty of AGs has been demonstrated in vitro for MDR-TB
strains [37]. Our results support the conclusion that the
bactericidal effect of AGs on MDR-TB in vivo is also
concentration-dependent. We found that increasing
amikacin dosages was associated with good treatment
outcome. Our analysis also demonstrated that there were
improved outcomes among MDR-TB patients treated with
amikacin for longer periods of time. As for the beneficial
effect of increasing amikacin dosage, we did not find dur-
ation of amikacin administration at which its beneficial ef-
fect plateaued. Currently, the WHO recommends using
an injectable drug as part of any MDR-TB regimen for
a minimum of 8 months [2]. However, data supporting
Table 1 Demographic and clinical characteristics of patients initiated on MDR-TB treatment
Hearing loss by type of diagnosis
Variables All patients
n = 437 n (%)
No hearing loss
n = 167 (38.2%)
n (%)
Hearing loss confirmed by
audiogram n = 147 (33.6%) n (%)
Clinical diagnosis of hearing
loss n = 123 (28.2%) n (%)
Sex Female 197 (45.1) 71 (42.5) 63 (42.9) 63 (51.2)
Male 240 (54.9) 96 (57.5) 84 (57.1) 60 (48.8)
Age category
in years
15 – 19 28 (6.4) 19 (11.4) 6 (4.1) 3 (2.4)
20 – 29 85 (19.5) 41 (24.6) 19 (12.9) 25 (20.3)
30 – 39 127 (29.0) 40 (24.0) 47 (32.0) 40 (32.5)
40 – 49 100 (22.9) 29 (17.4) 44 (29.9) 27 (22.0)
50 – 59 65 (14.9) 25 (15.0) 23 (15.7) 17 (13.8)
≥ 60 32 (7.3) 13 (7.8) 8 (5.4) 11 (8.9)
MDR-TB clinic Clinic 1 101(23.0) 36 (21.6) 27 (18.4) 38 (30.9)
Clinic 2 218 (50.0) 82 (49.1) 78 (53.1) 58 (47.1)
Clinic 3 35(8.0) 9 (5.4) 14 (9.2) 12 (9.8)
Clinic 4 40(9.2) 17 (10.2) 10 (6.8) 13 (10.6)





27 (6.2) 13 (7.8) 8 (5.4) 6 (4.9)
New TB regimen 142 (32.5) 59 (35.3) 38 (25.9) 45 (36.6)
Retreatment regimen 256 (58.6) 95 (56.9) 94 (64.0) 67 (54.5)
*Treated for MDR-TB 12 (2.7) 0 (0.0) 7 (4.8) 5 (4.1)
Outcome Completed 97 (22.2) 24 (14.4) 48 (32.7) 25 (20.3)
Cured 131 (30.0) 36 (21.6) 69 (46.9) 26 (21.1)
Death 53 (12.1) 29 (17.4) 10 (6.8) 14 (11.4)
Lost to follow up 10 (2.3) 4 (2.4) 3 (2.1) 5 (4.1)
Failure 22 (5) 7 (4.3) 5 (3.4) 8 (6.5)
On treatment 124 (28.4) 67 (40.1) 12 (8.2) 45 (36.6)
HIV HIV-uninfected 149 (34.1) 64 (38.3) 42 (28.6) 43 (35.0)
HIV-infected 288 (65.9) 103 (61.7) 105 (71.4) 80 (65.0)
On anti-retroviral
therapy
No 19 (7.0) 10 (9.7) 4 (3.8) 5 (6.2)
Yes 267 (93.0) 93 (90.3) 101 (96.2) 73 (93.8)
CD + T 4 cell count
cells/milliliter (mL)
category
< 50 cells/mL 44 (17.0) 16 (15.6) 16 (15.2) 12 (15.0)
50 – 199 cells/mL 52 (20.2) 17 (16.5) 21 (20.0) 14 (17.5)
200 – 350 cells/mL 96 (37.2) 32 (31.0) 38 (36.2) 26 (32.5)
> 350 cells/mL 66 (25.6) 38 (36.9) 30 (28.6) 28 (35.0)
*Previous history of MDR-TB treatment before enrolment in the study.
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this recommendation is sparse in the setting of prolonged
therapy and, perhaps, in the absence of severe adverse ef-
fects longer courses of AGs might be indicated.
The incidence of hearing loss in our cohort, was close
to 70% which is higher than what has been documented
from other countries, despite that the majority (75%) of
our patients were receiving an adequate dosage per
weight and renal function as per the WHO guidelines
[14,38,39]. Same as AG efficacy, adverse effects are both
time and concentration dependent. Consistently in our
study, development of hearing loss was independently
associated with amikacin duration and dosage. In
addition, these two risk factors showed an interaction
with each other. In other words, the risk of hearing
loss associated with amikacin treatment duration was
different (increased) with increasing treatment doses.
Although this interaction has been suggested by prior
studies, to our knowledge, we are the first demonstrating
Table 2 The Characteristics of amikacin dose and duration in patients on MDR-TB treatment







Total patients, n (%) 167 (38.2%) 147 (33.6%) 123 (28.2%)
Baseline (initial amikacin dose) dose/kg(kilogram) 17.0 (9.3 – 22.9) 17.2 (15.4 – 18.9) 17.2 (15.3 – 18.8)
Mean daily dose of amikacin (dose/kg/month) 16.2 (14.1 – 18.3) 16.7 (15.3 – 18.9) 16.6 (14.9 – 18.8)
Number of patients in whom amikacin administration was changed
from daily to 3 times per week
51 (30.5%) 131 (89.2%) 115 (93.5%)
Mean duration of daily amikacin treatment (days) 164 (2 – 429) 167 (105 – 210) 175 (126 – 213)
Mean duration of amikacin treatment given 3 times per week (days) 67 (2 – 336) 64 (41 – 105) 68 (42 – 108)
Overall duration of amikacin treatment (regardless of censoring; days) 189 (2 – 528) 195 (161 – 243) 200 (175 – 249)
Duration of amikacin treatment before censoring (days) 189 (42 – 632) 170 (104 – 212) 167 (108 – 214)
Table 3 Multivariate analysis of factors associated with risk of hearing loss among patients treated for MDR-TB
Hearing loss (diagnosed clinically
and through audiometry)
aOR (95% CI)
Hearing loss confirmed by
audiometry aOR (95% CI)
Hearing loss diagnosed
clinically aOR (95% CI)
Age category in years 15 – 29 years 1.00 1.00 1.00
30 – 39 years 3.8 (1.46 – 9.88) 2.88 (0.96 – 8.63) 4.89 (1.26 – 18.97)
40 – 49 years 5.21 (1.93 – 14.04) 4.49 (1.44 – 14.00) 5.57 (1.39 – 22.36)
≥ 50 years 2.78 (0.83 – 9.34) 1.99 (0.46 – 7.87) 4.12 (0.83 – 20.51)
Sex Female 1.00 1.00 1.00
Male 0.72 (0.46 – 1.37) 0.78 (0.467 – 1.30) 0.64 (0.37 – 1.11)
HIV status HIV infection 1.32 (0.83 – 2.12) 1.53 (0.89 – 2.62) 1.13 (0.62 – 2.06)
TB treatment history Never treated for
TB before
1.00 1.00 1.00
New TB regimen 1.24 (0.51 – 3.04) 1.01 (0.38 – 3.02) 1.47 (0.46 – 4.66)
Retreatment regimen 1.64 (0.69 – 3.91) 1.63 (0.60 – 4.36) 1.56 (0.51 – 4.78)
*Treated for MDR–TB Predicts outcome perfectly Predicts outcome perfectly Predicts outcome
perfectly
Mean creatinine clearance per
month in millilitre [mL]/minute
> 60 mL/minute 1.00 1.00 1.00
40 – 60 mL/minute 1.48 (1.05 – 2.09) 1.07 (0.50 – 2.28) 1.27 (0.54 – 2.98)
20 – 40 mL/minute 1.81 (0.87 – 3.75) 3.35 (1.07 – 10.53) 1.19 (0.29 – 4.82)
< 20 mL/minute 1.51 (0.67 – 3.36) 1.52 (0.34 – 6.71) 1.18 (0.25 – 5.40)
£Duration of amikacin treatment in months 1.98 (1.86 – 2.12) 1.85 (0.94 – 3.99) 1.93 (0.89 – 3.97)
¥Mean dose of amikacin per kilogram per month 1.15 (1.04 – 1.28) 1.11 (1.00 – 1.23) 1.18 (1.04 – 1.33)
Interaction between the duration of amikacin
treatment and amikacin dose
1.23 (1.11 – 1.35)
*Previous history of MDR–TB treatment before enrolment in the study, ¥aOR of amikacin dose indicates the increasing risk of ototoxicity per mg/kg/month,
£aOR of duration of amikacin treatment indicates the risk of ototoxicity per month.
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it in the treatment of MDR-TB patients, where the recom-
mended length of AG treatment may make this toxicity
issue more clinically relevant.
Although the incidence of hearing loss in our cohort is
perhaps the highest one reported to date, we believe that
this incidence might be an underestimate. As per our
definitions, we used highly specific criteria for the defin-
ition of hearing loss identified by audiometry. When au-
diograms were not available, hearing loss was defined by
evidence of hearing loss at conversational level. From
prior animal and human studies, we know that AGs ini-
tially cause irreversible high-frequency hearing loss by
destroying outer hair cells while sparing inner hair cells
[39-44]. This destruction gradually progresses into inner
hair cells of the cochlea, and by the time this damaging
effect becomes evident on a conventional pure-tone
audiogram or at conversational level, high-frequency
hearing has been already affected [17,39]. Fully consist-
ent with our findings, other clinical studies have shown
that patients who lose the ability to hear a conversation
at “whispering level” already have very advanced hearing
loss according to their audiograms. Therefore, we are
confident that patients who had evidence of hearing loss
during the physical exam would also have hearing loss
that could be detected by audiometry.
We did not find any association between hearing loss
and HIV infection. Although our bivariate analysis
showed an association between HIV infection and hear-
ing loss, this association disappeared after adjusting for
confounders. Thus, we believe that HIV infection by it-
self does not lead to a higher risk of developing hearing
loss but is likely associated with a myriad of factors that
by themselves or in combination increase the patient’s
risk of AG-induced hearing loss. There were several lim-
itations to this study. The therapeutic window of AGs is
narrow. Therefore abnormally high-plasma or serum
trough concentrations soon after starting therapy may
have been missed, as the only parameters used to select
the patient’s dose depended on weight and renal func-
tion in our population. We were also not able to obtain
early audiograms for all our patients. Thus, it is highly
likely that many patients already had some degree of
hearing impairment at the time of the start of amikacin
therapy, particularly those who had been on retreatment
regimen. Due to limitations in our data, we were not
able to analyse prior use of AGs. However, we found that
history of MDR-TB treatment which could be a good
surrogate for prior AG treatment. Similarly, given the
lack of audiograms for some patients, we cannot confirm
that the hearing loss we observed was sensorineural and
that AGs were responsible for the hearing loss. We also
depended on the diagnosis of hearing loss by physicians,
which was not fully standardized and was performed, in
most cases, only when hearing loss was severe. Medica-
tions other than ART, which may have been ototoxic
or protective, were not accounted for. Our analyses
included all patients at risk for ototoxicity. Our implicit
assumption was that all patients have an equal risk of
development of ototoxicity at any point in time. Since
patients on treatment are at risk for the development of
the outcome, they were also included in the analyses.
We acknowledge that this assumption might not be ab-
solutely true (given potential differences in susceptibility
and other confounders). However, after adjustment for
Table 4 Multivariate analysis of factors associated with good clinical outcomes among patients treated for MDR-TB
Good treatment outcomes
among all MDR TB patients
aOR (95% CI)
Good treatment outcomes (excluding
patients with hearing loss diagnosed
clinically) aOR (95% CI)
Good treatment outcomes (excluding
patients with hearing loss diagnosed
by audiometry) aOR (95% CI)
Sex Female 1.00 1.00 1.00
Male 0.72 (0.4 –1.21) 0.71 (0.42 – 1.19) 0.72 (0.44 – 1.21)






New TB regimen 0.93 (0.27 – 3.23) 0.71 (0.19 – 2.64) 0.75 (0.20 – 2.77)
Retreatment
regimen
0.60 (0.18 – 1.98) 0.48 (0.13 – 1.69) 0.48 (0.14 – 1.70)
*Treated for
MDR TB
0.16(0.09 – 0.67) 0.12 (0.02 – 0.70) 0.11 (0.02 – 0.57)
Renal failure at any point 0.61 (0.36 – 0.98) 0.46 (0.22 – 0.94) 0.52 (0.12 – 1.01)
Duration of amikacin treatment
(in months)
1.13(1.06 – 1.21) 1.14 (1.06 – 1.21) 1.14 (1.05 – 1.22)
¶Mean dose of amikacin per
kilogram per month
1.90 (1.12 – 2.99) 1.90 (1.79 – 3.00) 1.88 (1.18 – 3.99)
*History of MDR–TB treatment before enrolment in the study, ¶Minimum dose 13 mg/kg.
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confounders and particularly time in the study, we be-
lieve it provides the most robust analyses to look into
the relationship between AGs and ototoxicity.
Conclusions
MDR-TB will continue to be a global health problem for
many years to come. Although new and promising drugs
are in the pipeline, it seems likely that AG-based regi-
mens will continue to be the standard of care in many
resource-limited settings. Therefore, prospective research
studies to determine the best balance between the benefits
and adverse effects of these drugs are critical. Future stud-
ies must investigate inexpensive, easy-to implement inter-
ventions to identify early AG-related hearing loss.
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